Compare SURG & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SURG | IXHL |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | United States | Australia |
| Employees | 20 | N/A |
| Industry | Advertising | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 97.6M |
| IPO Year | N/A | 2024 |
| Metric | SURG | IXHL |
|---|---|---|
| Price | $0.78 | $4.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | 166.4K | ★ 4.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | $3.78 | N/A |
| Revenue Next Year | $113.46 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.75 | $0.11 |
| 52 Week High | $3.47 | $5.17 |
| Indicator | SURG | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 33.42 | 85.43 |
| Support Level | $0.75 | $0.31 |
| Resistance Level | $0.95 | $5.17 |
| Average True Range (ATR) | 0.06 | 0.28 |
| MACD | 0.03 | 0.36 |
| Stochastic Oscillator | 20.96 | 81.26 |
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.